ASN95 -- Selected abstracts: Hemodialysis (excluding access, hepatitis)

Sun. Nov. 5 1995

9:30 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Hemodialysis access

Program number 183 Board# S183 at 10:45 A.M.
* Effect of hemodialysis access on delivered dose of dialysis (Kt/V). K.M. Erbeck, M.E. Brier, P. DeOreo, R.J. Hamburger and R.A. Ward. - Louisville, KY.

Program number 189 Board# S189 at 10:45 A.M.
* Continuous veno-venous hemodialysis In septic patients. M. Manns, M.H. Sigler and B.P. Teehan. - Wynnewood, PA.

Program number 208 Board# S208 at 10:45 A.M.
* Phosphate removal during conventional hemodialysis and slow nocturnal home hemodialysis. I. Mucsi, G. Hercz, M. Ouwendyk, L. Wallace, B. Francoeur and R. Uldall. - Budapest, Hungary and Toronto, Canada.

Program number 209 Board# S209 at 10:45 A.M.
* In vitro clearance of advanced glycosylated end-products by conventional and high-flux hemodialysis membranes. S. Fishbane, J. Maesaka, T. Mitsuhashi, G. Adam and H. Vlassara. - Mineola and Manhasset, NY.

Program number 210 Board# S210 at 10:45 A.M.
* Pharmacokinetics of recombinant hirudin in hemodialyzed patients. R. Vanholder, A. Camez, A.M. Dhondt, A. Van Loo and S. Ringoir. - Gent, Belgium.

Program number 212 Board# S212 at 10:45 A.M.
* Mass transfer characterization of vancomycin removal by high-flux cellulosic hemodialyzers. W. Clark, M. Scott, B. Mueller, M. Kraus and W. Macias. - McGaw park, Il and Indianapolis, IN.

Program number 218 Board# S218 at 10:45 A.M.
* Intradialytic changes in circulating lipids with anticoagulation by the low molecular weight heparin enoxaparin. R.Khurana, R.F. Gagnon, K. Cianflone, J. Leclerc and M. Vasilevsky. - Montreal,Canada.

Program number 220 Board# S220 at 10:45 A.M.
* Safety ofhemodialysis machines: Surveillance of the venous blood return. F. Dellanna, D. Stippel, W. Schmitz and C.A. Baldamus. - Cologne, Germany.

Program number 221 Board# S221 at 10:45 A.M.
* Hemodialysis in patients with high risk of hemorrhage: Prostacyclin versus citrate versus heparin free HD. R. Ponikvar, J. Buturovic, M. Benedik, A. Urban, A. Licina and J. Varl. - Ljubljana, Slovenia.

Program number 222 Board# S222 at 10:45 A.M.
* Beta2-microglobulin removal is possible with low flux membranes. R.A. Ward, A. Buscaroli, S. Stefoni, B. Schmidt, H.J. Gurland and H. Klinkmann. - Louisville, KY; Bologna, Italy; Munich, Germany and Glasgow, Scotland.

Program number 223 Board# S223 at 10:45 A.M.
* Treatment of volume overload in patients with acute renal failure by intermittent hemodialysis. W. Clark, B. Mueller, M. Kraus and W. Macias.- McGaw Park, IL and Indianapolis, IN.

Program number 225 Board# S225 at 10:45 A.M.
* Effect of blood flow rate on urea rebound in hemodialysis patients. H.S. Kim, S.K. Shin and D.H. Kim. - Suwon, Korea.

9:30 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Dialysis adequacy: Estimates and results

Program number 229 Board# S229 at 10:45 A.M.
* The multinational study of dialysis therapy: Dialysis dose. A.J. Bleyer, A.P. Disney, B. Hylander, Y. Nomoto, P.T.H. Coates, A.Borklund, E. De la Torre and J.M. Burkart. - Winston-Salem; NC, Adelaide, Australia; Stockholm, Sweden and Isehara City, Japan.

Program number 232 Board# S232 at 10:45 A.M.
* Hemodialysis high efficiency treatments: 6 years outcomes. J.P. Bosch, G.J. Mishkin, V. Barlee and B. Von Albertini.- Washington, DC.

Program number 233 Board# S233 at 10:45 A.M.
* Prescribed versus delivered dialysis in the intensive care unit. L. Moreno, M. Leblanc, P. Ellis, L. Kozlowski and E.P. Paganini. - Cleveland, OH.

Program number 235 Board# S235 at 10:45 A.M.
* Hemodialysis treatment dose is an independent determinant of seven year survival. N. Mittman, M.M. Avram, L. Bonomini, K. Oo, J. Licht and R. Sreedhara. - Brooklyn, NY.

Program number 238 Board# S238 at 10:45 A.M.
* Limitations of formula conversions of Kt/V for predicting rebound and equilibrated Kt/V. G.J. Mishkin, J.P. Bosch, J.Garcia-Valdecasas, V. Barlee and B. Von Albertini. - Washington, DC.

Program number 239 Board# S239 at 10:45 A.M.
* An analysis of errors in a urea rebound prediction algorithm. S.W. Smye and E.J. Will. - Leeds, United Kingdom.

Program number 241 Board# S241 at 10:45 A.M.
* A simplified method for measuring normalized protein catabolism during a single hemodialysis. T.A. Depner and J.T. Daugirdas. - Davis, Caand Chicago, IL.

Program number 253 Board# S253 at 10:45 A.M.
* Cardiopulmonary recirculation: Theory and in vitro evaluation. D. Schneditz, K. Martin and N.W. Levin. - Graz, Austria and New York, NY.
9:30 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Uremia/toxins

Program number 599 Board# S599 at 10:45 A.M.
* Accumulation of pentosidine in free and albumin-binding formin hemodialysis patients. T. Miyata, Y. Ueda, T.Shinzato, Y. Iida and K. Maeda. - Nagoya and Osaka, Japan.

4:00 P.M. ---minisymposia--- San Diego Conv Ctr Rm 5ab
Adequacy of dialysis

Program number 623 at 4:15
* Comparison of 2 year survival on hemodialysis and peritoneal dialysis with dose of dialysis matched using the peak concentration hypothesis. P. Keshaviah, J. Ma, K. Thorpe, D. Churchill and A. Collins. - Minneapolis, MN and Hamilton, Canada.

Program number 626 at 5:00
* Comparison of mortality risk by Kt/V single pool versus doublepool analysis in diabetic and non-diabetic hemodialysis patients. N.W. Levin, D.C. Stannard, F. Gotch and F.K. Port. - Ann Arbor, MI.

Program number 627 at 5:15
* Factors associated with center-to-center variations in the adequacy of hemodialysis. W.McClellan, R. Caruana and J. Krisher. - Atlanta, GA and Raleigh, NC.

Mon. Nov. 6 1995

9:00 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Hemodynamic/cardiovascular relationships of dialysis/end-stage renal disease

Program number 797 Board# M66 at 10:00 A.M.
* Increased atherogenic risk of diabetic patients undergoing hemodialysis: role of modified, triglyceride-rich lipoproteins. A. Kramer-Guth, M. Schomig, M. Keller, M.W. Baumstark, J. Thiery, W. Marz, P. Schollmeyer and C. Wanner. - Munich and Wurzburg, Germany.

Program number 800 Board# M69 at 10:00 A.M.
* Heparin-induced increased nitric oxide production is a cause for hypotension during hemodialysis. K. Yokokawa, M.G. Saklayen and A.K. Mandal. - Dayton, Oh and Osaka, Japan.

Program number 802 Board# M71 at 10:00 A.M.
* Decrease in middle cerebral arterial blood velocity after hemodialysis In the newly initiated HD patients. I. Ishida, H. Hirakata, T. Omae, H. Sugimori, H. Kanai, S. Ibayashi, S. Okuda and M. Fujishima. - Fukuoka, Japan.

Program number 803 Board# M72 at 10:00 A.M.
* Effects of hemodialysis on cerebral blood flow and function. J.W. Lohr, K.Z. Donnelly, B.W. Murphy, H. Khalak, R. Schrot and A.H.Lockwood. - Buffalo, NY.

Program number 804 Board# M73 at 10:00 A.M.
* Declining incidence of dialysis-associated pericarditis in end stage renal disease patients on hemodialysis. K.S. Modi, D.L. Bowlin, J. Mah and A.C. Collins. - Minneapolis, MN.

Program number 805 Board# M74 at 10:00 A.M.
* Sudden cardiac death and autonomic nerve dysfunction in hemodialysis patients. H. Takahashi, S. Matsuo, T. Toriyama, H. Kawahara and J-I. Hayano. - Nagoya, Japan.

Program number 807 Board# M76 at 10:00 A.M.
* Cardiac disease in endstage renal disease: A comparison of hemodialysis and peritoneal dialysis. J.D. Harnett, G. Kent, R. Foley, D. Murray, P. Barre and P. Parfrey. - St. John's and Montreal, Canada.

Program number 810 Board# M79 at 10:00 A.M.
* Bioimpedance spectroscopy for assessment of fluid distribution in hemodialysis patients and normal adults. B.J. Fisch and D.M. Spiegel. - Denver, Co.

Program number 811 Board# M80 at 10:00 A.M.
* Variable conductivity and ultrafiltration in maintenance hemodialysis: comparison study of 4 associations. D. Mercier, B. Francois, S. Mercier and M. Labeeuw. - Lyon, France.

Program number 812 Board# M81 at 10:00 A.M.
* Relationship between blood volume and inferior vena cava diameter during and after short and long hemodialysis. K.S. Katzarski, J.Nisell and J. Bergstrom. - Huddinge, Stockholm and Mora, Sweden.

Program number 813 Board# M82 at 10:00 A.M.
* Does circulating endothelin participate in the volume-dependent arterial pressure control in dialysis patients? F. Mallamaci, S. Parlongo, M. Postorino and C. Zoccali. - Reggio Calabria, Italy.

Program number 814 Board# M83 at 10:00 A.M.
* Is "big-endothelin" a marker of heart failure in hemodialysis patients? I. Odar-Cederlof, A. Hemsen, J.M. Lundberg, F. Ericsson and C.M. Kjellstrand. - Stockholm, Sweden and Edmonton, Canada.

Program number 815 Board# M84 at 10:00 A.M.
* Assessment of dry weight in hemodialysis with inferior vena cava diameter, plasma atrial natriuretic peptide and hydration of free fat mass. M. Ortiz, R. Jalil, M. Campano, G. Soto, R. Urzua, S. Braun, A. Vaccarezza and A. Valdivieso. - Santiago, Chile.

Program number 816 Board# M85 at 10:00 A.M.
* Nitric oxide regulation in response to volume contraction in pediatric patients on hemodialysis. R.P. Woroniecki, Y. Mishra, H-L. Fung, J.B. Van Liew, M.I. Woroniecki and L.G. Feld. - Buffalo, NY.

Program number 817 Board# M86 at 10:00 A.M.
* The effect of fluid loading on blood pressure in hemodialysis patients. A.J. Luik, J. Spek, W. Van Kuijk, F. De Heer, J.P. Van Hooff and K.M.L. Leunissen. - Maastricht and Sittard, The Netherlands.

Program number 818 Board# M87 at 10:00 A.M.
* The effect of different ultrafiltration rates on hemodynamic parameters in cardiac compromised patients and patients with a normal cardiac function. F.M. Van der Sande, W.H.M. Van Kuijk and K.M.L. Leunissen. - Maastricht, The Netherlands.

Program number 819 Board# M88 at 10:00 A.M.
* Use of continuous blood volume monitoring to predict intradialytic events during hemodialysis: Effect of constant versus varying ultrafiltration. A. Jabara and R. Mehta. - San Diego, CA.

Program number 820 Board# M89 at 10:00 A.M.
* Increased interdialytic weight gain is associated with left ventricular hypertrophy in white hemodialysis patients. O. Ifudu, M. Dawood, P. Homel and E.A. Friedman. - Brooklyn, NY.

Program number 851 Board# M120 at 10:00 A.M.
* Beta-2 microglobulin amyloidosis involving the GI tract in hemodialysis. D.A. Price, B. Gunes, J.R. Turner, J.M. Lazarus and J. Kay. - Burlington and Boston, MA.

Program number 852 Board# M121 at 10:00 A.M.
* Incidence of bacteremia in hemodialysis patients 1993-1994. B.A.J. Walters, M. Molina, A.F. Rosenthal, V. Didominic and S.J. Bander. - Nashville, TN.

Program number 853 Board# M122 at 10:00 A.M.
* Rehabilitation outcomes in home hemodialysis. A.G. Bellucci, N. Kapikian, L.U. Mailloux, B. Napolitano, R.T. Mossey, M. Vernace, B. Wilkes and I. Miller. - Manhasset, NY.

Program number 855 Board# M124 at 10:00 A.M.
* The multinational study of dialysis therapy: Patient compliance. A. Disney, A.J. Bleyer, B. Hylander, Y. Nomoto, P.T.H.Coates, E. De la Torre, A. Bjorklund and J.M. Burkart. - Winston-Salem, NC; Adelaide, Australia; Stockholm, Sweden; and Isehara City, Japan.

Program number 867 Board# M136 at 10:00 A.M.
* Use of vancomycin in high-flux hemodialysis: Experience with 108 courses. R.H. Barth, N. De Vincenzo and B. Patel. - Brooklyn, NY.

Program number 869 Board# M138 at 10:00 A.M.
* Activated protein C resistance in patients on hemodialysis. B.S. Hoch, I.U. Nawabi, M.Cicero, S.J. Shahmehdi, B.M. Louis, C. Hernandez, N. Namboodiri, G. Neiderman, S. Borra and H.I. Lipner. - Brooklyn, NY.

Program number 870 Board# M139 at 10:00 A.M.
* Advanced glycation endproducts markers are elevated both in diabetic and non-diabetic hemodialyzed patients. N. Kobayashi, K. Kumano, K. Kamata, A. Yoshida, T. Nagaoka, M. Shirataka, A. Takeuchi, Y. Kobayashi, M. Okubo and H. Kobayashi. - Sagamihara, Japan.

Program number 873 Board# M142 at 10:00 A.M.
* Residual renal function in hemodialysis and continuous ambulatory peritoneal dialysis patients. B. Bhatla, K.D. Nolph, H. Moore, B. Prowant, Z. Twardowski, R. Khanna and G. Petroski. - Columbia, MO.

Program number 889 Board# M158 at 10:00 A.M.
* Comparison of total survival of dialysis only and dialysis/transplant patients. J. Ma, P. Grambsch, A. Collins, B. Kasiske and V. Rao. - Minneapolis, MN.

Program number 891 Board# M160 at 10:00 A.M.
* A multidisciplinary predialysis program - lack of effect on outpatient hemodialysis initiation. D.C. Mendelssohn, I. Hare and E.C. Porter. - Toronto, Canada.

Program number 892 Board# M161 at 10:00 A.M.
* Predictors of short-term mortality in diabetic hemodialysis patients. R.A. Ward, M.E. Brier, P. Deoreo, K.M. Erbeck, R.J. Hamburger and B.A. Smith. - Louisville, KY; Cleveland, OH and Indianapolis, IN.

Program number 894 Board# M163 at 10:00 A.M.
* Quality oflife and behavioral compliance in hemodialysis patients. P.L. Kimmel, K. Weihs, R. Peterson, S. Simmens, D.Boyle, W. Umana, J. Veis and I. Cruz. - Washington, DC.

Program number 896 Board# M165 at 10:00 A.M.
* Severe neuropathy predicts mortality in non-diabetic hemodialysis patients. N. Mittman, M.M. Avram, A. Castanares, K. Oo, J. Licht and R. Sreedhara. - Brooklyn, NY.

Program number 898 Board# M167 at 10:00 A.M.
* The relationship between dialysis adequacy and survival at one center. A.J. Bleyer, R. D'Agostino and J.M. Burkart. - Winston-Salem, NC.

Program number 899 Board# M168 at 10:00 A.M.
* Adequacy of dialysis and nutritional status of U.S. Hemodialysis patients. S. Helgerson, W. McClellan and S. Beaver. - Atlanta, GA and Seattle, WA.

9:00 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Dialysis and outcome in acute renal failure

Program number 903 Board# M172 at 10:00 A.M.
* Effect of hemodialysis after contrast media application in adults with renal insufficiency. T. Lehnert, K. Gondolf, T. Schaffner, P. Schollmeyer and E. Keller. - Freiburg, Germany.

Program number 905 Board# M174 at 10:00 A.M.
* Advantages of continuous veno-venous hemodialysis In acute renal failure. M. Manns, M.H. Sigler and B.P. Teehan. - Wynnewood, PA.

Program number 925 Board# M194 at 10:00 A.M.
* Renal replacement therapy in allogeneic versus autologous bone marrow transplantation. K.M. Erbeck, A.A. Jacobs, B.A. Smith, M.E. Brier and d.A. Stevens. - Louisville, KY.
9:00 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Metabolism in end-stage renal disease

Program number 961 Board# M230 at 10:00 A.M.
* Bio-incompatibility appears to enhance phosphate (PO4) removal during hemodialysis. C. Kjellstrand, S. Jacobson, I. Odar-Cederlof and P. Kjellstrand. - Edmonton, Canada and Sweden.

Program number 969 Board# M238 at 10:00 A.M.
* Increased homocysteine values, A risk factor for premature coronary artery disease, prevail in patients on hemodialysis. A. Gupta,D. Chaudhuri, K. Robinson, D.W. Jacobsen and V.W. Dennis. - Cleveland, OH.

Program number 971 Board# M240 at 10:00 A.M.
* Influence of hemodialysis on lipid peroxidation products. M. Daschner, H. Lenhartz, D. Botticher, F. Schaefer, O. Mehls and M. Leichsenring.- Heidelberg, Germany.

Program number 972 Board# M241 at 10:00 A.M.
* Lipoprotein lipase activity and mass in hemodialysis patients. T. Tabe, Y. Ohtsubo, K. Takenouchi, Y. Uchida, Y. Yasumoto, W. Yamashita and T. Arima. - Kagoshima, Japan.

Program number 976 Board# M245 at 10:00 A.M.
* Effects of polysulfone hemodialysis membrane on serum lipids and apo c in vivo and in vitro. K. Takenouchi, Y. Ohtsubo, T. Tabe, M. Matsuda, Y. Uchida, Y. Yasumoto, W. Yamashita and T. Arima. - Kagoshima, Japan.

Program number 980 Board# M249 at 10:00 A.M.
* Fluctuations of urea generation rate following protein intake in hemodialysis patients measured using 13-C-urea. W.D. Kloppenburg, B.G. Wolthers, T. Tepper, C.A. Stegeman, P.E. De Jong and R.M. Huisman. - Groningen, The Netherlands.

Program number 981 Board# M250 at 10:00 A.M.
* Determinationof NPCR without prior calculation of Kt/V. B.O. Lightfoot, L.L. Mulloy and R.J. Caruana. - Augusta, GA.

Program number 982 Board# M251 at 10:00 A.M.
* Comparison of the accuracy of the BCP and BCG methods for the determination of serum albumin concentration in hemodialysis patients. A.F.Rosenthal, M. Day, S. Lin, B.A.J. Walters and S.J. Bander. - Ft. Lauderdale, FL.

Program number 989 Board# M258 at 10:00 A.M.
* Energy expenditure related to body composition in chronic hemodialysis patients. H.W. Van Hamersvelt, I. Van Haelst, W. Diemont, A.H.J. Naber, P. Deurenberg and R.A.P. Koene. - Nijmegen and Wageningen, The Netherlands.

Program number 990 Board# M259 at 10:00 A.M.
* Blood glucose determination in diabetic hemodialysis patients. C.A. Frankenburg, J.A. Hasbargen and R.L. Roudebush. - Indianapolis, IN.

Program number 991 Board# M260 at 10:00 A.M.
* Influence of body composition on insulin sensitivity and dyslipidaemia in patients on chronic haemodialysis. P. Lee, G. Jones, D. O'Neal, B. Murphy and J.D. Best. - Fitzroy, Australia.

Program number 994 Board# M263 at 10:00 A.M.
* Nitrogen balance in hospitalized chronic hemodialysis patients. T.A. Ikizler, J.H. Wingard and R.M. Hakim.- Nashville, TN.

Program number 995 Board# M264 at 10:00 A.M.
* Predictors of malnutrition in maintenance hemodialysis patients. A.R. Qureshi, B. Anderstam, A. Danielsson, A. Gutierrez, B. Lindholm and J. Bergstrom. - Huddinge and Stockholm, Sweden.

Program number 996 Board# M265 at 10:00 A.M.
* High cytokine levels may mediate the high mortality of hemodialysis patients with low albumin and/or cholesterol. R.M. Bologa, D.M. Levine, T.S. Parker, D. Serur, K.H. Stenzel, A. Rubin and J.S. Cheigh. - New York, NY.

Program number 999 Board# M268 at 10:00 A.M.
* Effect of protein supplement on nutritional status in hemodialysis patients. P. Ivarsen and E.B. Pedersen. - Aarhus,Denmark.

Program number 1003 Board# M272 at 10:00 A.M.
* Protein intake responds to increases in Kt/V despite baseline Kt/V > 1.2. R.G. Marcus, E. Cohl and J. Uribarri. - New York, NY.

Program number 1004 Board# M273 at 10:00 A.M.
* Can we reconcile metabolic acidosis and nutritional status in hemodialysis patients? S.R. Acchiardo, L. Moore, S.O. Smith, S. Testerman, L.B. Burk, S.J. Smith and K. Will. - Memphis, TN.

Program number 1005 Board# M274 at 10:00 A.M.
* Bicarbonate kinetics and protein catabolism in dialysis patients. S. David, C. Caserta, V. Giancaspro and V. Cambi. - Parma, Italy.

Program number 1006 Board# M275 at 10:00 A.M.
* Plasma glucose turnover and oxidation during hemodialysis: Caloric benefit of dialysis. C.L. Skutches and M.H. Sigler. -Wynnewood, PA.

Program number 1007 Board# M276 at 10:00 A.M.
* Vitamin and mineral intake in stable chronic hemodialysis patients. M. Rocco, D. Poole, P. Poindexter and J. Burkart. - Winston-Salem, NC.
9:00 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Modeling in dialysis: Techniques and applications II

Program number 1013 Board# M282 at 10:00 A.M.
* Sequential measure of extracellular fluid during and after hemodialysis using bioimpedance spectroscopy. W. Zaluska, A.M. Kaufman, A.T. Morris, Y. Wang, H.D. Polaschegg and N.W. Levin. - New York, NY.

Program number 1014 Board# M283 at 10:00 A.M.
* Fractional direct dialysis quantification: New approach for prescription and monitoring of chronic hemodialysis therapy. C. Charytan, B. Gupta and B. Spinowitz. - Flushing, NY.

Program number 1017 Board# M286 at 10:00 A.M.
* The protective effect of cool dialysate is dependant on patients pre dialysis temperature. A. Fine, L. Janzen and B.Penner. - Winnipeg, Canada.

Program number 1018 Board# M287 at 10:00 A.M.
* Interest of simultaneous multifrequency body and plasmatic extracorporeal impedance metries in patients on hemodialysis. V. Joyeux, M.P. Morin, A. Guerard, J. Rivalan and P. Lepogamp. - Rennes, France.

Program number 1023 Board# M292 at 10:00 A.M.
* Measurements of urea rebound in hemodialysis patients and their implications. S.R. Acchiardo, L. Moore, S.O. Smith, L.B. Burk, S.J. Smith and K. Will. - Memphis, TN.

Program number 1025 Board# M294 at 10:00 A.M.
* Comparison of acetate-Free and bicarbonate dialysate in hemodialysis. D-X. Ji, H-L. X and L-S. Li. - Nanjing,China.

Program number 1026 Board# M295 at 10:00 A.M.
* Capillary filtration coefficient and refilling rate as influenced by ultrafiltration and/or sodium profiling during hemodialysis. A. Knoflach, H. Kubista and U. Binswanger. - Zurich, Switzwerland.

Program number 1027 Board# M296 at 10:00 A.M.
* Accuracy of the on-line urea kinetic modelling: Urea removal and urea reduction ratio. J.L. Poignet, P. Chauveau, J.F. Dessassis, B. Zins and C. Naret. - Paris, France.

Program number 1031 Board# M300 at 10:00 A.M.
* Assessing hemodialysis efficiency and dietary intake in the individual patient: How many measurements are required? W.D. Kloppenburg, R. Stewart, C.A. Stegeman, P.E. De Jong and R.M. Huisman. - Groningen, The Netherlands.

Program number 1032 Board# M301 at 10:00 A.M.
* Single and double pool calculation of mean BUN during hemodialysis as an estimation of urea disequilibrium. M. Manns, M.H. Sigler and B.P. Teehan. - Wynnewood, PA.

4:00 P.M. ---Free communications--- San Diego Conv Ctr Rm 5ab
Access for and methods of dialysis I

Program number 1362 at 5:15
* Significant reduction of plasma LDL-apo B and glycated apo B follows chronic high-flux hemodialysis in diabetic uremic patients. S. Fishbane, R. Bucala, T. Koschinsky, D. Giordano, H. Founds and H. Vlassara. - Manhasset and Mineola, NY; Dusseldorf, Germany and NJ.

4:00 P.M. ---Free Communications--- San Diego Conv Ctr Rm 8
Beta-2 microglobulin: Importance in end-stage renal disease

Program number 1376 at 4:45
* Participation of apolipoprotein E in the formation of beta 2-microglobulin amyloid in hemodialysis patients. Beta 2-m has a binding capacity to apo E. S. Miyazaki, T. Yamamoto, T. Morita, F. Ogata, Y. Koda, Y. Yuasa, S. Sakai, M. Suzuki, S. Takahashi, I. Kihara and Y. Hirasawa. - Niigata, Japan.

Tue. Nov. 7 1995

9:00 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Hypertension: Clinical II

Program number 1520 Board# T70 at 10:00 A.M.
* Acute effect of recombinant human erythropoietin on blood pressure and vasoactive substances in chronic hemodialysis patients. M. Doumoto, A. Tojo, K. Kimura, K. Oka, S. Yagi and H.Matsuoka. - Tochigi and Tokyo, Japan.

Program number 1540 Board# T90 at 10:00 A.M.
* Effect of blood pressure on survival in a prevalent cohort of hemodialysis patients. P.G. Zager, M. Campbell, R. Brown and D. Peterson.- Nashville, TN.

9:00 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Complications and outcomes in end-stage renal disease III

Program number 1595 Board# T145 at 10:00 A.M.
* Adequacy of dialysis and subsequent morbidity and mortality among adult U.S. hemodialysis patients. J. Lowery, W. McClellan and S. Helgerson.- Atlanta, GA and Seattle, WA.

Program number 1596 Board# T146 at 10:00 A.M.
* Home hemodialysis patients exhibit superior survivals. L. Mailloux, A. Bellucci, B. Napolitano, N. Kapikian, R. Mossey, M. Vernace, I. Miller and B. Wilkes. - Manhasset, NY.

Program number 1604 Board# T154 at 10:00 A.M.
* Association of serum bicarbonate to survival in hemodialysis: A nonlinear relationship. N. Mittman, M.M. Avram, R. Loutoby and R. Sreedhara. - Brooklyn, NY.

Program number 1605 Board# T155 at 10:00 A.M.
* Patient mix and mortality in chronic hemodialysis. R.A. Wolfe, E. Mauger, P.J. Held, T. Golper, I. Sarsitis, J.D. Woods, L.Y.C. Agodoa and F.K. Port. - Ann Arbor, MI.

Program number 1610 Board# T160 at 10:00 A.M.
* A switch from conventional to high performance membrane can reduce a risk of carpal tunnel syndrome and mortality of hemodialysis patients. Y. Koda, S. Miyazaki, M. Suzuki, Y. Hirasawa and T. Nishi. - Niigata and Tokyo, Japan.

Program number 1611 Board# T161 at 10:00 A.M.
* Pulmonary hypertension in hemodialysis patients. N. Saffarian, J. Piriz, F. Visco and M. Dave. - Bronx, NY.

Program number 1612 Board# T162 at 10:00 A.M.
* Preoperative vancomycin prophylaxis decreases the incidence of hemodialysis vascular access infections. G.B. Zibari, M.F. Gadallah, M.D. Landreneau, R. McMillan, R. Bridges, K. Costley, J. Work and J.C. McDonald. - Shreveport, LA.

9:00 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Access methods of peritoneal dialysis

Program number 1620 Board# T170 at 10:00 A.M.
* Access-related infection in HIV sero positive dialysis patients: comparison of hemodialysis to peritoneal dialysis. J.A. Vassalotti, M.Choi, A. Whelton, W. Briggs, L. Gimenez and P.J. Scheel. - Baltimore, MD.

9:00 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Membrane effects in end-stage renal disease

Program number 1650 Board# T200 at 10:00 A.M.
* Positive feedback in cuprophan membrane-induced neutrophil degranulation. T. Masaki and A.K. Cheung. - Salt Lake City, UT.

Program number 1651 Board# T201 at 10:00 A.M.
* Variable response by neutrophils to stimuli following exposure to cuprophan membrane. A. Cheung, S. Wei, J. Leypoldt and T. Masaki. - Salt Lake City, UT.

Program number 1653 Board# T203 at 10:00 A.M.
* Discordance between neutropenia and monocytopenia during hemodialysis. A.K. Cheung, J.K. Leypoldt and R.B. Deeter. - Salt Lake City, UT.

Program number 1654 Board# T204 at 10:00 A.M.
* Novel potential therapeutic activity of cuprophan dialysis membranes. C. Gunther, J. Vienken and A. Mahiout. - Wuppertal and Hannover, Germany.

Program number 1656 Board# T206 at 10:00 A.M.
* Cytokine production during in vitro hemodialysis with new, and formaldehyde or renalin-reprocessed cellulose dialyzers. B.J.G. Pereira, B. Snodgrass, C. Perella, G. Barber, S. Chopra and A.J. King. - Boston, MA.

Program number 1659 Board# T209 at 10:00 A.M.
* Hemodialysis hypotension is mediated by cytokines. E.C. Manning, J.Y. Cheung, l.M. Demers and N. Ahsan. - Hershey, PA.

Program number 1660 Board# T210 at 10:00 A.M.
* Effect of ultrafiltered dialysate on the induction of IL- receptor antagonist in patients on HD with polysulfone and modified cellulose triacetate. S. Krautzig, G. Lonnemann, S. Shaldon and K.M. Koch.- Hannover, Germany and Nimes, France.

Program number 1667 Board# T217 at 10:00 A.M.
* Polysulfone -a comparison of three brands. N. Hoenich and C. Woffindin. - Newcastle, United Kingdom.

Program number 1668 Board# T218 at 10:00 A.M.
* Cellulose diacetate a new membrane for haemodialysis. N. Hoenich and C. Woffindin. - Newcastle, United Kingdom.

Program number 1670 Board# T220 at 10:00 A.M.
* Effect of renalin reprocessing on small and large solute clearances by hemodialyzers. J.K. Leypoldt, A.K. Cheung and R.B.Deeter. - Salt Lake City, UT.

Program number 2103 at 4:00
* The relationship of dialysis membrane and cause-specific mortality in chronic hemodialysis patients. W.E. Bloembergen, F.K. Port, R.M. Hakim, D. Stannard, R.A. Wolfe, L.Y.C. Agodoa and P.J. Held. - Ann Arbor, MI.

Program number 2104 at 4:15
* Dialysis room and reuse strategies that affect the incidence of hepatitis C infection in HD units. J. Pinto dos Santos, A. Loureiro, C.S. Schmid, R. Ruthazer and B.J.G. Pereira. - Boston, MA.

Program number 2107 at 5:00
* Survival of type II diabetic native American Indians on hemodialysis Is better than caucasians. C.A.I. Hirata-Dulas, D.C. Dahl, K. Modi, J.Z. Ma, A.J. Collins and W.F. Keane. - Minneapolis, MN.

Program number 2109 at 5:30
* Hemodialysis decreases muscle protein synthesis in healthy volunteers. E.Lofberg, J. Wernerman, P. Essen, M. McNurlan, P. Garlick and J. Bergstrom. - Stockholm, Sweden and Stony Brook, NY.

Wed. Nov. 8 1995

10:00 A.M. ---Free Communications--- San Diego Conv Ctr Rm 5a
Dialysis adequacy: Applications and outcomes

Program number 2177 at 11:00
* Kt/V corrected for double pool kinetics accurately predicts urea removal, equilibrium Kt/V, and URR. M.M. Bankhead, R.D. Toto and R.A. Star. - Dallas, TX.

10:00 A.M. ---Free communications--- San Diego Conv Ctr Rm 8
Nutrition and metabolism in dialysis patients

Program number 2217 at 10:00
* Dietary intake and nutritional status in the hemo pilot study population. j.T. Dwyer,J.D. Kopple, B.J. Maroni, J.D. Burrowes, S.N. Powers, D.B. Cockram, W.C. Chumlea, J.W. Kusek, R.Makoff, P.J. Cunniff, D.J. Goldstein and l. Paranandi. - Bethesda, MD.

Program number 2218 at 10:15
* Elevated serum C-reactive protein is a strong predictor ofincreased mortality and low serum albumin in hemodialysis patients. J. Bergstrom, O. Heimburger, B. Lindholm and A.R. Qureshi. - Huddinge and Stockholm, Sweden.

Program number 2219 at 10:30
* A cross-sectional study of body composition in hemodialysis patients. G.M. Chertow, E.G. Lowrie, N.L. Lew, J. Ling and J.M. Lazarus. - Boston and Waltham, MA.

Program number 2220 at 10:45
* Provision of amino acids by dialysis during maintenance hemodialysis. C. Chazot,E. Shahmir, B. Matias and J.D. Kopple. - Torrance, CA.

Use BACK arrow on your browser (faster) or click here to go back to ASN95 main page

UP Click on ARROW for HDCN Home Page.